Amendments to the Claims: This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (Currently Amended) <u>A device Device</u> for detecting one or more analytes in a sample, <u>the device comprising:</u>

one or more reaction chambers (1), suited adapted to receive a the sample, as well as, optionally, one or more reagent application channels (2),

including one or more capillary systems (3) following onto the reaction chambers (1) or the reagent application channels (2), and

one or more negative vessels—(4) following onto the capillary system or the capillary systems—(3).

- 2. (Currently Amended) <u>The device Device</u>-according to claim 1, wherein-a each of the capillary systems system (3) includes comprises at least one capillary (3b) of a capillary plane (3a) or one or more capillaries (3b), which present a diminished cross-section in one or more capillary planes (3a).
- 3. (Currently Amended) <u>The device Device</u>-according to claim 1 or 2, wherein <u>each</u> of the capillary <u>systems</u>-system (3) includes <u>comprises</u> capillary planes (3a) of diminishing cross-section, which are disposed one below the other.
- 4. (Currently Amended) <u>The device Device</u>-according to any one of claims 1 to 3_2, wherein in each capillary plane (3b) a plurality of capillaries—(3b) are arranged in an adjoining or bundled fashion.
- 5. (Currently Amended) <u>The device Device according to claim 4 any one of claims 1</u> to 4, wherein adjoining or bundled capillaries (3b) of a capillary plane (3a) include additionally comprise connecting webs-(8).
- 6. (Currently Amended) <u>The device Device</u>-according to <u>claim 4</u> any one of claims 1 to 5, wherein adjoining or bundled capillaries (3b) of a capillary plane (3a) have the same inner cross-sectional area.

- 7. (Currently Amended) The device Device-according to any one of claims 1 to $\frac{6}{2}$, wherein, the more distant the inner cross-sectional area of the capillary planes $\frac{3}{3}$ is disposed from the reaction chamber $\frac{1}{3}$, the smaller it becomes.
- 8. (Currently Amended) The device Device-according to any one of claims 1 to 7 2, wherein the capillary planes (3a) of the capillary system (3) are connected by chambers, whose inner cross-sectional area is preferably the same as that of the largest capillary (3b).
- 9. (Currently Amended) <u>The device Device</u>-according to any one of claims 1 to <u>8 2</u>, wherein the reagent application channel—(2) has <u>1,2 1.2</u> times the volume compared with the capillary <u>(3b)</u> or the capillary system—(3) plus the negative vessel—(4).
- 10. (Currently Amended) <u>The device Device-according</u> to any one of claims 1 to <u>9_2</u>, wherein the negative vessel—(4) has a larger volume than the volume of the compacted sediment of the cells or particles used.
- 11. (Currently Amended) <u>The device Device</u> according to any one of claims 1 to <u>10</u> <u>2</u>, wherein the negative vessel (4) has a shape, which tapers towards the bottom, for example pointed like an arrow or U shaped.
- 12. (Currently Amended) <u>The device Device</u>-according to any one of claims 1 to <u>11</u> <u>2</u>, from which one or <u>more a plurality of ventilation channels branch channel(s) (6) branches/branch off, preferably from the upper, wider portion of the negative vessel.</u>
- 13. (Currently Amended) <u>The device Device</u> according to any one of claims 1 to <u>12</u> 2, wherein the capillary system—(3) forms an integral component of the carrier element—(5).
- 14. (Currently Amended) <u>A method Method</u> for detecting one or more analytes in a sample fluid by the <u>visualisation visualization</u> of agglutination, the method comprising the <u>steps of:-characterised in that</u>
- a) <u>contacting the sample fluid is brought into contact</u> with a reagent to form a <u>reaction mixture</u>,
- b) <u>exposing</u> the reaction mixture is exposed to the effects of gravitation or magnetism, <u>and passing</u> the reaction mixture <u>passing</u> through the capillary system of the

device according to <u>claim 1</u> one of claims 1 to 13, followed by a negative vessel of the device according to <u>claim 1</u>, one of claims 1 to 13

and

- c) <u>determining</u> the reaction between the analyte and the reagent-is determined.
- 15. (Currently Amended) <u>The method Method</u> according to claim 14, wherein the reaction mixture is brought into contact with a further reagent during process step b).
- 16. (Currently Amended) The method Method according to claim 14, wherein the order of the individual process steps consisting of a) and b) are reversed, in particular when the sample fluid is brought into contact with a reagent only during the action of gravitation or magnetism.
- 17. (Currently Amended) <u>The method Method</u> according to any one of claims 14 to 16, wherein the sample fluid and/or the reagent include one or more particles.
- 18. (Currently Amended) <u>The method Method</u> according to any one of claims 14 to 17 16, wherein the reaction is determined optically.
- 19. (Currently Amended) <u>The method Method</u> according to any one of claims 14 to <u>18-16</u>, wherein the particles have a natural-colour colour or are coloured colored.
- 20. (Currently Amended) <u>The method Method</u> according to any one of claims 14 to <u>19-16</u>, wherein the particles are <u>colour_color-</u>, radio-, fluorescent- or enzyme-coded.
- 21. (Currently Amended) <u>The method Method</u> according to any one of claims 14 to 20-16, wherein the particles include erythrocytes and/or thrombocytes and/or leucocytes or parts thereof.
- 22. (Currently Amended) <u>The method Method</u> according to any one of claims 14 to 21 16, wherein the particles are pre-treated with proteolytic enzymes in order to enhance the reaction.
- 23. (Currently Amended) The method Method according to any one of claims 14 to 22 16, wherein antibodies selected from the group consisting of, in particular peptides,

proteins, carbohydrates, lipids, nucleic acids, viruses, bacteria, parasites, human cells, animal cells, or plant cells, and or parts thereof are bound to the particles.

- 24. (Currently Amended) <u>The method Method</u> according to any one of claims 14 to 23–16, wherein antigens or other ligands, such as, e.g. peptides, proteins, carbohydrates, lipids, nucleic acids, viruses, bacteria, parasites, human cells, animal cells, plant cells or allergens or parts thereof are bound to the particles.
- 25. (Currently Amended) <u>The method Method</u> according to any one of claims 14 to <u>24-16</u>, wherein the particles in particular comprise polystyrene, polybromostyrene, gelatine, melamine, polymerised agarose or polymethyl methacrylate.
- 26. (Currently Amended) <u>The method Method</u> according to any one of claims 14 to <u>25-16</u>, wherein the particles are magnetic or paramagnetic.
- 27. (Currently Amended) <u>The method Method</u> according to any one of claims 14 to <u>26–16</u>, wherein the sample mixture is exposed to gravitation by being subjected to centrifuging.
- 28. (Currently Amended) <u>The method Method</u> according to any one of claims 14 to 27 16, wherein the sample mixture is exposed to magnetism.
- 29. (Currently Amended) <u>The method Method</u> according to any one of claims 14 to <u>28–16</u>, wherein the sample fluid comprises human, animal or plant material, in particular blood or blood components.
- 30. (Currently Amended) <u>The method Method</u> according to any one of claims 14 to 29-16, wherein the reagent comprises in particular antibodies, test cells, synthetic particles, buffers or booster solutions.
- 31. (Currently Amended) <u>The method Method</u> according to any one of claims 14 to 30–16, wherein <u>glycerine glycerin</u> or other molecules are added to the reagent in order to increase the specific density of the solution.
- 32. (Currently Amended) The method according to any one of claim 14 to 16 in which at least one of the following is determined or detected: Use of the device according to an one of claims 1 to 13, in particular in blood group serological diagnostics, preferably for

determining blood groups, antibodies against blood group characteristics, of-compatibilities between stored blood and recipients, for determining—thrombocyte characteristics and antibodies directed against thrombocytes, for determining—leucocyte characteristics and antibodies directed against leucocytes, for detecting—haemagglutinating viruses, for detected antibodies against proteins, viruses, bacteria, parasites, for detecting—viral or bacterial or parasitic or other antigens,—and/or for detecting auto-antibodies, and antibodies directed against allergens.

33. (New) The method according to claim 24 in which the other ligands are selected from the group consisting of peptides, proteins, carbohydrates, lipids, nucleic acids, viruses, bacteria, parasites, human cells, animal cells, plant cells, allergens, and parts thereof.